Andrew Potter joined what became Vernalis in 1998 after PhD and post-doctoral work at the Universities of Liverpool and Nottingham. As a medicinal chemist, he has a wide range of experience in discovery efforts towards RNA, kinase and PPI targets in CNS and oncology areas. He has been involved with, and coordinated, drug discovery collaborations in the US, Japan and France, from hit ID to late-stage lead optimisation. Andrew is responsible for academic outreach and business development.
